Lawrence R. Nycum

OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Carol Aghajanian, Stephanie V. Blank, Barbara A. Goff et al. · Journal of Clinical Oncology · 2012 · 1.4K citations · Full text

Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer

Carol Aghajanian, Barbara A. Goff, Lawrence R. Nycum et al. · Gynecologic Oncology · 2015 · 306 citations · Full text

Medicine, Cancer Management, Gynecology +8

Age-Specific Survival of Women with Endometrioid Adenocarcinoma of the Uterus

John Farley, Lawrence R. Nycum, Michael J. Birrer et al. · Gynecologic Oncology · 2000 · 45 citations

Uterine Fibroids, Gynecological Surgery, Gynecology +7

OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC).

C. Aghajanian, N. Finkler, T. Rutherford et al. · Journal of Clinical Oncology · 2011 · 35 citations

Immunology, Gynecology, Platinum-sensitive Recurrent +21

Asian-Pacific Islander race independently predicts poor outcome in patients with endometrial cancer☆☆The views expressed herein are those of the authors and do not reflect the official opinion of the Department of Defense or the United States Army or Air Force.

Edward R. Kost, Kevin L. Hall, Jeffrey F. Hines et al. · Gynecologic Oncology · 2003 · 30 citations

Air Force, Cancer Risk, Cancer Epidemiology +11